Inspire Q3 Revenue Falls 7.9% to $206.7M; FY26 Guidance Narrowed, New CPT Code Set for 2028
INSP sits 73% above its 52-week low of $38.91.
Summary
Inspire posted Q3 revenue of $206.7 million, down 7.9% year over year but up 3.0% sequentially, with adjusted EPS of $0.14 after $24.1 million of restructuring charges. Full-year revenue guidance was narrowed to $850-$860 million, and a new Category I CPT code for single-lead HGNS takes effect January 1, 2028.
Key Events · Earnings and Guidance · INSP
-
Q3 Revenue Down 7.9% Y/Y
Revenue was $206.7 million versus $224.5 million a year ago, a 7.9% decline driven by U.S. coding and reimbursement challenges, though it rose 3.0% sequentially.
-
GAAP Loss on Restructuring, Settlement
Operating expenses rose 12.8% to $206.6 million on $24.1 million of Project Horizon restructuring charges and $7.0 million of legal settlement expense, producing a net loss of $24.4 million, or $(0.84) per diluted share; adjusted diluted EPS was $0.14.
-
FY26 Guidance Narrowed
Revenue outlook narrowed to $850-$860 million from $835-$875 million, adjusted operating margin to 4.5%-5.5% and adjusted diluted EPS to $1.20-$1.40; management anticipates only low-single-digit growth in 2027.
-
New CPT Code Effective January 2028
The AMA CPT Editorial Panel approved a new Category I CPT code for single-lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028.
Analysis · INSP · Industrial Applications And Services
Revenue fell 7.9% year over year to $206.7 million as U.S. coding and reimbursement disruption kept physicians cautious, but the 3.0% sequential gain suggests the worst may be passing. The quarter swung to a GAAP net loss of $24.4 million, or $(0.84) per diluted share, largely on $24.1 million of Project Horizon restructuring charges and a $7.0 million legal settlement; adjusted EPS was $0.14. Management narrowed full-year revenue to $850-$860 million from $835-$875 million and now guides adjusted EPS of $1.20-$1.40, while flagging only low-single-digit growth in 2027. The offsetting positive is the AMA CPT Editorial Panel's September approval of a dedicated Category I code for single-lead hypoglossal nerve stimulation, effective January 1, 2028, which should remove the coding ambiguity that has weighed on procedure volumes.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INSP was trading at $67.15 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $38.91 to $147.03. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.